Gsa Capital Partners LLP Solid Biosciences Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$0.74 - $1.79 $83,696 - $202,456	-113,104 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $21,111 - $30,730	12,492 Added 12.42%	113,104 $198,000
Q3 2021 Nov 12, 2021	BUY	$2.38 - $3.77 $239,456 - $379,307	100,612 New	100,612 $240,000
Q4 2020 Feb 03, 2021	SELL	$3.08 - $7.79 $40,523 - $102,493	-13,157 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$2.02 - $3.08 $5,506 - $8,396	2,726 Added 26.13%	13,157 $27,000
Q2 2020 Aug 11, 2020	SELL	$2.1 - $3.42 $20,124 - $32,773	-9,583 Reduced 47.88%	10,431 $31,000
Q1 2020 May 12, 2020	BUY	$2.31 - $4.43 $46,232 - $88,662	20,014 New	20,014 $48,000
Q2 2019 Aug 06, 2019	SELL	$4.6 - $10.13 $57,361 - $126,321	-12,470 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$7.19 - $32.37 $89,659 - $403,653	12,470 New	12,470 $115,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.